Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Overview
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Companies Involved in Therapeutics Development
Baergic Bio Inc
Cerevel Therapeutics LLC
NeuroCycle Therapeutics Inc
Sanio AB
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Drug Profiles
BAER-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-865 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAN-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Discontinued Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Product Development Milestones
Featured News & Press Releases
Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigatiol therapy in development for the treatment of Epilepsy
Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigatiol Epilepsy treatment
Feb 18, 2019: Sanios SAN711 selected for clinical studies in itching and pain
Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004
Dec 04, 2017: Sanio Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Baergic Bio Inc, H2 2020
Pipeline by Cerevel Therapeutics LLC, H2 2020
Pipeline by NeuroCycle Therapeutics Inc, H2 2020
Pipeline by Saniona AB, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020